Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A

https://ift.tt/f3IjFmz

from Sanofi - Aventis Groupe https://ift.tt/Nh9RAtc
via IFTTT